

1FW



MM DOCS\1-PAT\PAT 2003\APP\1241-03 Pharma Blood\1241 Suppl IDS - Cert.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eduardo M. Lasalvia-Prisco
Serial No.: 10/607,358
Filing Date: June 26, 2003
For: METHOD AND COMPOSITION TO ELICIT AN EFFECTIVE
AUTOLOGOUS ANTITUMORAL IMMUNE RESPONSE IN A
PATIENT

Confirmation No. 6124
Customer No. 04219
Hong Sang, Examiner
Group Art Unit 1643

2800 S.W. Third Avenue
Historic Coral Way
Miami, Florida 33129

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

CERTIFICATE OF MAILING


I HEREBY CERTIFY that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 9 day of August, 2006.

Respectfully submitted,

MALLOY & MALLOY, P.A.
2800 S.W. Third Avenue
Historic Coral Way
Miami, Florida 33129
(305) 858-8000

By: John Fulton, Jr.
John Fulton, Jr.
Reg. No. 46,716

Date: August 9, 2006



DOCS\1-PAT\PA 2003\APP\1241- 03 Pharma Blood\1241 IDS-Trans Notice.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eduardo M. Lasalvia-Prisco

Serial No.: 10/607,358

Filing Date: June 26, 2003

For: METHOD AND COMPOSITION TO ELICIT AN EFFECTIVE
AUTOLOGOUS ANTITUMORAL IMMUNE RESPONSE IN A PATIENT

Confirmation No. 6124
Customer No. 04219
Hong Sang, Examiner
Group Art Unit 1643

2800 S.W. Third Avenue
Historic Coral Way
Miami, Florida 33129

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure, the attached information is provided for consideration by the U.S. Patent and Trademark Office in connection with the above-captioned application. The information is identified on the attached form PTO/SB/08B.

The Applicant notes that this Information Disclosure Statement is being presented after the issuance of a first Office Action, but before the issuance of a final action or Notice of Allowance. Thus, in accordance with 37 CFR §1.97(c) and 37 CFR §1.97(e):

That each item of information contained in this


Information Disclosure Statement filed herewith was first cited in an International Search Report in a counterpart application filed under the Patent Cooperation Treaty, and, to the knowledge of the undersigned, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR §1.56(c) more than three (3) months prior to the filing of this Information Disclosure Statement.

The Examiner is respectfully requested to return an initialed copy of form PTO/SB/08B enclosed herewith evidencing consideration of this information with the next Office Action.

Respectfully submitted,


MALLOY & MALLOY, P.A.
Attorneys for Applicant
2800 S.W. Third Avenue
Historic Coral Way
Miami, Florida 33129
(305) 858-8000

By:


John Fulton, Jr.
Reg. No. 46,716

Dated:

August 9, 2006



PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1A-100

FIRST SUPPLEMENTAL

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/607,358
Filing Date	June 26, 2003
First Named Inventor	Eduardo M. Lasalvia-Prisco
Art Unit	1643
Examiner Name	Hong Sang
Attorney Docket Number	1.241.03

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KATO et al., Stimulation of the Stress-Induced Expression of Stress Proteins by Curcumin in Cultured Cells . . . , Cell Stress & Chaperones, Sept 1998, Vol 3, No 3, pp. 152-160	
		AMBERGER et al., Suppressive Effects of Anti-Inflammatory Agents on Human Endothelial Cell Activation . . . , Mol Med., Feb 1999, Vol 5, No 2, pp. 117-128	
		ITO et al., Enhancement of Stress-Induced Synthesis of hsp27 and [alpha-beta] Crystallin by Modulators . . . , J Cell Physiol., Feb 1996, Vol 166, No 2, pp. 332-339	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

FIRST SUPPLEMENTAL**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/607,358
Filing Date	June 26, 2003
First Named Inventor	Eduardo M. Lasalvia-Prisco
Art Unit	1643
Examiner Name	Hong Sang
Attorney Docket Number	1.241.03

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KATO et al., Stimulation of the Stress-Induced Expression of Stress Proteins by Curcumin in Cultured Cells . . . , Cell Stress & Chaperones, Sept 1998, Vol 3, No 3, pp. 152-160	
		AMBERGER et al., Suppressive Effects of Anti-Inflammatory Agents on Human Endothelial Cell Activation . . . , Mol Med., Feb 1999, Vol 5, No 2, pp. 117-128	
		ITO et al., Enhancement of Stress-Induced Synthesis of hsp27 and [alpha-beta] Crystallin by Modulators . . . , J Cell Physiol., Feb 1996, Vol 166, No 2, pp. 332-339	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.